• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

住院 COVID-19 患者血浆中脯氨酸特异性肽酶活性（DPP4、PRCP、FAP 和 PREP）。

Proline-specific peptidase activities (DPP4, PRCP, FAP and PREP) in plasma of hospitalized COVID-19 patients.

机构信息

Laboratory of Medical Biochemistry, Department of Pharmaceutical Sciences, University of Antwerp, Belgium.

Institute of Tropical Medicine, Antwerp, Belgium; Clinical Virology Unit, Institute of Tropical Medicine, Antwerp, Belgium.

出版信息

Clin Chim Acta. 2022 Jun 1;531:4-11. doi: 10.1016/j.cca.2022.03.005. Epub 2022 Mar 10.

DOI:10.1016/j.cca.2022.03.005
PMID:35283094
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8920094/
Abstract

BACKGROUND

COVID-19 patients experience several features of dysregulated immune system observed in sepsis. We previously showed a dysregulation of several proline-selective peptidases such as dipeptidyl peptidase 4 (DPP4), fibroblast activation protein alpha (FAP), prolyl oligopeptidase (PREP) and prolylcarboxypeptidase (PRCP) in sepsis. In this study, we investigated whether these peptidases are similarly dysregulated in hospitalized COVID-19 patients.

METHODS

Fifty-six hospitalized COVID-19 patients and 32 healthy controls were included. Enzymatic activities of DPP4, FAP, PREP and PRCP were measured in samples collected shortly after hospital admission and in longitudinal follow-up samples.

RESULTS

Compared to healthy controls, both DPP4 and FAP activities were significantly lower in COVID-19 patients at hospital admission and FAP activity further decreased significantly in the first week of hospitalization. While PRCP activity remained unchanged, PREP activity was significantly increased in COVID-19 patients at hospitalization and further increased during hospital stay and stayed elevated until the day of discharge.

CONCLUSION

The changes in activities of proline-selective peptidases in plasma are very similar in COVID-19 and septic shock patients. The pronounced decrease in FAP activity deserves further investigation, both from a pathophysiological viewpoint and as its utility as a part of a biomarker panel.

摘要

背景

COVID-19 患者表现出几种免疫系统失调的特征，这些特征在脓毒症中也观察到过。我们之前曾显示，在脓毒症中几种脯氨酸选择性肽酶（如二肽基肽酶 4（DPP4）、成纤维细胞激活蛋白 α（FAP）、脯氨酰寡肽酶（PREP）和脯氨酰羧肽酶（PRCP））失调。在这项研究中，我们研究了这些肽酶是否在住院 COVID-19 患者中同样失调。

方法

纳入 56 名住院 COVID-19 患者和 32 名健康对照者。在入院后不久采集样本并进行纵向随访样本，测量 DPP4、FAP、PREP 和 PRCP 的酶活性。

结果

与健康对照组相比，COVID-19 患者入院时 DPP4 和 FAP 活性均显著降低，且 FAP 活性在入院后第一周进一步显著降低。PRCP 活性保持不变，而 PREP 活性在 COVID-19 患者入院时显著升高，并在住院期间进一步升高，直至出院日仍保持升高。

结论

COVID-19 患者和脓毒性休克患者血浆中脯氨酸选择性肽酶活性的变化非常相似。FAP 活性的明显下降值得进一步研究，既从病理生理学的角度，也从其作为生物标志物组分之一的实用性角度。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c59c/8920094/52829fc40609/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c59c/8920094/965864b93ce3/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c59c/8920094/2bf726d4026d/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c59c/8920094/52829fc40609/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c59c/8920094/965864b93ce3/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c59c/8920094/2bf726d4026d/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c59c/8920094/52829fc40609/gr3_lrg.jpg

相似文献

1
Proline-specific peptidase activities (DPP4, PRCP, FAP and PREP) in plasma of hospitalized COVID-19 patients.住院 COVID-19 患者血浆中脯氨酸特异性肽酶活性（DPP4、PRCP、FAP 和 PREP）。
Clin Chim Acta. 2022 Jun 1;531:4-11. doi: 10.1016/j.cca.2022.03.005. Epub 2022 Mar 10.
2
Dysregulated activities of proline-specific enzymes in septic shock patients (sepsis-2).脓毒性休克患者（sepsis-2）中脯氨酸特异性酶活性失调。
PLoS One. 2020 Apr 21;15(4):e0231555. doi: 10.1371/journal.pone.0231555. eCollection 2020.
3
The development and validation of a combined kinetic fluorometric activity assay for fibroblast activation protein alpha and prolyl oligopeptidase in plasma.开发并验证了一种用于血浆中成纤维细胞激活蛋白α和脯氨酰寡肽酶的联合动力学荧光活性测定法。
Clin Chim Acta. 2019 Aug;495:154-160. doi: 10.1016/j.cca.2019.04.063. Epub 2019 Apr 11.
4
Beta-endoproteolysis of the cellular prion protein by dipeptidyl peptidase-4 and fibroblast activation protein.二肽基肽酶 4 和成纤维细胞激活蛋白对细胞朊病毒蛋白的β-末端蛋白水解作用。
Proc Natl Acad Sci U S A. 2023 Jan 3;120(1):e2209815120. doi: 10.1073/pnas.2209815120. Epub 2022 Dec 27.
5
Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity.酰化甘氨酰-(2-氰基)吡咯烷类作为成纤维细胞激活蛋白 (FAP) 的抑制剂及 FAP/脯氨酰寡肽酶 (PREP) 选择性的问题。
Bioorg Med Chem Lett. 2012 May 15;22(10):3412-7. doi: 10.1016/j.bmcl.2012.03.107. Epub 2012 Apr 4.
6
Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-α.神经肽 Y、B 型利钠肽、P 物质和肽 YY 是成纤维细胞激活蛋白-α的新型底物。
FEBS J. 2011 Apr;278(8):1316-32. doi: 10.1111/j.1742-4658.2011.08051.x. Epub 2011 Mar 9.
7
Unravelling the immunological roles of dipeptidyl peptidase 4 (DPP4) activity and/or structure homologue (DASH) proteins.揭示二肽基肽酶4（DPP4）活性和/或结构同源物（DASH）蛋白的免疫作用。
Clin Exp Immunol. 2016 Jun;184(3):265-83. doi: 10.1111/cei.12757. Epub 2016 Mar 2.
8
Prolyl peptidases: a serine protease subfamily with high potential for drug discovery.脯氨酰肽酶：一个具有高药物研发潜力的丝氨酸蛋白酶亚家族。
Curr Opin Chem Biol. 2003 Aug;7(4):496-504. doi: 10.1016/s1367-5931(03)00084-x.
9
Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity.基于二肽底物特异性的成纤维细胞活化蛋白蛋白酶的选择性抑制
J Biol Chem. 2006 Mar 17;281(11):7437-44. doi: 10.1074/jbc.M511112200. Epub 2006 Jan 12.
10
Potential disease biomarkers: dipeptidyl peptidase 4 and fibroblast activation protein.潜在的疾病生物标志物：二肽基肽酶4和成纤维细胞活化蛋白。
Protoplasma. 2018 Jan;255(1):375-386. doi: 10.1007/s00709-017-1129-5. Epub 2017 Jun 16.

引用本文的文献

1
Identification and validation of mA RNA methylation and ferroptosis-related biomarkers in sepsis: transcriptome combined with single-cell RNA sequencing.脓毒症中 mA RNA 甲基化与铁死亡相关生物标志物的鉴定及验证：转录组联合单细胞 RNA 测序
Front Immunol. 2025 Mar 7;16:1543517. doi: 10.3389/fimmu.2025.1543517. eCollection 2025.
2
Immunopathological markers and cell types linked to COVID-19 symptom manifestation.与 COVID-19 症状表现相关的免疫病理标志物和细胞类型。
BMC Infect Dis. 2024 Nov 4;24(1):1237. doi: 10.1186/s12879-024-10139-z.
3
ACE2, ACE, DPPIV, PREP and CAT L enzymatic activities in COVID-19: imbalance of ACE2/ACE ratio and potential RAAS dysregulation in severe cases.

本文引用的文献

1
The Protective Role of Prolyl Oligopeptidase (POP) Inhibition in Kidney Injury Induced by Renal Ischemia-Reperfusion.脯氨酰寡肽酶（POP）抑制在肾缺血再灌注损伤中的保护作用。
Int J Mol Sci. 2021 Nov 2;22(21):11886. doi: 10.3390/ijms222111886.
2
Exhausted NK cells and cytokine storms in COVID-19: Whether NK cell therapy could be a therapeutic choice.COVID-19 中的耗竭 NK 细胞和细胞因子风暴：NK 细胞疗法是否可能成为一种治疗选择。
Hum Immunol. 2022 Jan;83(1):86-98. doi: 10.1016/j.humimm.2021.09.004. Epub 2021 Sep 8.
3
The C-terminal cleavage of angiotensin II and III is mediated by prolyl carboxypeptidase in human umbilical vein and aortic endothelial cells.
COVID-19 中的 ACE2、ACE、DPPIV、PREP 和 CAT L 酶活性：严重病例中 ACE2/ACE 比值失衡和潜在的 RAAS 失调。
Inflamm Res. 2023 Aug;72(8):1719-1731. doi: 10.1007/s00011-023-01775-3. Epub 2023 Aug 3.
4
Vascular risk factors for COVID-19 ARDS: endothelium, contact-kinin system.新冠病毒感染所致急性呼吸窘迫综合征的血管危险因素：内皮、接触激肽系统。
Front Med (Lausanne). 2023 Jun 28;10:1208866. doi: 10.3389/fmed.2023.1208866. eCollection 2023.
5
Arrhythmias after COVID-19 Vaccination: Have We Left All Stones Unturned?新冠病毒疫苗接种后心律失常：我们是否已彻底研究过所有问题？
Int J Mol Sci. 2023 Jun 20;24(12):10405. doi: 10.3390/ijms241210405.
6
The spike effect of acute respiratory syndrome coronavirus 2 and coronavirus disease 2019 vaccines on blood pressure.急性呼吸综合征冠状病毒 2 型和 2019 年冠状病毒病疫苗对血压的尖峰效应。
Eur J Intern Med. 2023 Mar;109:12-21. doi: 10.1016/j.ejim.2022.12.004. Epub 2022 Dec 13.
7
Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology.二肽基肽酶-4（DPP4）在新型冠状病毒肺炎病理生理学中的作用
Biomedicines. 2022 Aug 19;10(8):2026. doi: 10.3390/biomedicines10082026.
8
COVID-19, vaccines and deficiency of ACE and other angiotensinases. Closing the loop on the "Spike effect".COVID-19、疫苗和 ACE 及其他血管紧张素转换酶缺乏症。对“刺突效应”闭环。
Eur J Intern Med. 2022 Sep;103:23-28. doi: 10.1016/j.ejim.2022.06.015. Epub 2022 Jun 22.
血管紧张素 II 和 III 的 C 端切割由脯氨酰羧肽酶在人脐静脉和主动脉内皮细胞中介导。
Biochem Pharmacol. 2021 Oct;192:114738. doi: 10.1016/j.bcp.2021.114738. Epub 2021 Aug 19.
4
Regulation of Inflammatory Cytokine Storms by Mesenchymal Stem Cells.间充质干细胞对炎症细胞因子风暴的调控。
Front Immunol. 2021 Jul 29;12:726909. doi: 10.3389/fimmu.2021.726909. eCollection 2021.
5
Fibroblast Activation Protein-Specific PET/CT Imaging in Fibrotic Interstitial Lung Diseases and Lung Cancer: A Translational Exploratory Study.成纤维细胞激活蛋白特异性 PET/CT 成像在肺纤维化性间质性肺疾病和肺癌中的应用：一项转化性探索性研究。
J Nucl Med. 2022 Jan;63(1):127-133. doi: 10.2967/jnumed.121.261925. Epub 2021 Jul 16.
6
The Counter Regulatory Axis of the Lung Renin-Angiotensin System in Severe COVID-19: Pathophysiology and Clinical Implications.严重 COVID-19 中肺肾素-血管紧张素系统的反向调节轴：病理生理学和临床意义。
Heart Lung Circ. 2021 Jun;30(6):786-794. doi: 10.1016/j.hlc.2020.11.008. Epub 2020 Dec 9.
7
A Novel Purification Procedure for Active Recombinant Human DPP4 and the Inability of DPP4 to Bind SARS-CoV-2.活性重组人二肽基肽酶4（DPP4）的新型纯化方法及DPP4与严重急性呼吸综合征冠状病毒2（SARS-CoV-2）结合的无能性
Molecules. 2020 Nov 18;25(22):5392. doi: 10.3390/molecules25225392.
8
The role of prolyl oligopeptidase, understanding the puzzle.脯氨酰寡肽酶的作用：解读谜团
Ann Transl Med. 2020 Aug;8(16):983. doi: 10.21037/atm-20-3412.
9
Circulating dipeptidyl peptidase-4 is independently associated with the presence and severity of NAFLD/NASH in individuals with and without obesity and metabolic disease.循环二肽基肽酶-4与肥胖和代谢性疾病患者及非肥胖和代谢性疾病患者的非酒精性脂肪性肝病/非酒精性脂肪性肝炎的存在和严重程度独立相关。
J Endocrinol Invest. 2021 May;44(5):979-988. doi: 10.1007/s40618-020-01392-5. Epub 2020 Aug 27.
10
DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications?糖尿病与新冠病毒肺炎中的二肽基肽酶4和血管紧张素转换酶2：心血管并发症的治疗靶点？
Front Pharmacol. 2020 Aug 7;11:1161. doi: 10.3389/fphar.2020.01161. eCollection 2020.